Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

P. P. Sordillo; C. B. Magill; R. J. Gralla; D. P. Kelsen

doi:10.1097/00000421-198206000-00006

Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

P. P. Sordillo, C. B. Magill, R. J. Gralla, D. P. Kelsen

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m², every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

Original language	English (US)
Pages (from-to)	273-275
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	5
Issue number	3
DOIs	https://doi.org/10.1097/00000421-198206000-00006
State	Published - 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198206000-00006

Cite this

@article{cc5e885e9c66422ab0bcf21491f51e59,

title = "Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma",

abstract = "A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.",

author = "Sordillo, {P. P.} and Magill, {C. B.} and Gralla, {R. J.} and Kelsen, {D. P.}",

year = "1982",

doi = "10.1097/00000421-198206000-00006",

language = "English (US)",

volume = "5",

pages = "273--275",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

AU - Sordillo, P. P.

AU - Magill, C. B.

AU - Gralla, R. J.

AU - Kelsen, D. P.

PY - 1982

Y1 - 1982

N2 - A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

AB - A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020316214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020316214&partnerID=8YFLogxK

U2 - 10.1097/00000421-198206000-00006

DO - 10.1097/00000421-198206000-00006

M3 - Article

C2 - 6896259

AN - SCOPUS:0020316214

SN - 0277-3732

VL - 5

SP - 273

EP - 275

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 3

ER -

Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this